دورية أكاديمية
The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout.
| العنوان: | The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout. |
|---|---|
| المؤلفون: | Wilson LC; Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand., Ward J; Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand., Wright DFB; School of Pharmacy, University of Otago, Dunedin, New Zealand.; Sydney Pharmacy School, University of Sydney, Sydney, New South Wales, Australia., Green SC; Department of Medicine, University of Otago, Christchurch, New Zealand., Stocker SL; Sydney Pharmacy School, University of Sydney, Sydney, New South Wales, Australia.; Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.; Sydney Musculoskeletal Health, Univ. of Sydney, Sydney, New South Wales, Australia., Putt TL; Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand., Schollum JBW; Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand., Walker RJ; Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand. |
| المصدر: | Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2024 Aug; Vol. 29 (8), pp. 547-550. Date of Electronic Publication: 2024 Apr 16. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1797 (Electronic) Linking ISSN: 13205358 NLM ISO Abbreviation: Nephrology (Carlton) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Carlton, Vic., Australia : Blackwell Science, |
| مواضيع طبية MeSH: | Uric Acid*/blood , Gout*/drug therapy , Gout*/blood , Peritoneal Dialysis* , Oxypurinol*/pharmacokinetics , Gout Suppressants*/pharmacokinetics , Gout Suppressants*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Aged ; Allopurinol/therapeutic use ; Allopurinol/pharmacokinetics ; Renal Elimination ; Half-Life ; Dialysis Solutions/pharmacokinetics |
| مستخلص: | Gout affects 15%-30% of individuals with advanced kidney disease. Allopurinol which is rapidly and extensively metabolised to an active metabolite, oxypurinol, is the most commonly prescribed urate-lowering therapy. Oxypurinol is almost entirely eliminated by the kidneys (>95%) and has an elimination half-life of 18-30 h in those with normal kidney function. However, oxypurinol pharmacokinetics are poorly understood in individuals with kidney failure on peritoneal dialysis. This study characterised the elimination of oxypurinol and urate in people with gout receiving peritoneal dialysis. Oxypurinol steady-state oral clearance (CL/F), elimination half-life as well as kidney (CL (© 2024 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.) |
| References: | Yeo E, Palmer SC, Chapman PT, Frampton C, Stamp LK. Serum urate levels and therapy in adults treated with long‐term dialysis: a retrospective cross‐sectional study. Intern Med J. 2019;49(7):838‐842. Cohen S, Kimmel P, Neff R, Agodoa L, Abbott K. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19:2204‐2210. Richette P, Doherty M, Pascual E, et al. 2016 updated European League Against Rheumatism evidence‐based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29‐42. doi:10.1136/annrheumdis‐2016‐209707. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744‐760. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623‐644. Hishe HZ, Stocker SL, Stamp LK, et al. The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics. Clin Transl Sci. 2023;16(3):422‐428. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31‐41. doi:10.1159/000180580. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323‐345. |
| معلومات مُعتمدة: | Otago Medical Research Foundation Jack Thomson Award |
| فهرسة مساهمة: | Keywords: gout; oxypurinol pharmacokinetics; peritoneal dialysis; urate elimination |
| المشرفين على المادة: | 268B43MJ25 (Uric Acid) G97OZE5068 (Oxypurinol) 0 (Gout Suppressants) 63CZ7GJN5I (Allopurinol) 0 (Dialysis Solutions) |
| تواريخ الأحداث: | Date Created: 20240416 Date Completed: 20240720 Latest Revision: 20240720 |
| رمز التحديث: | 20240721 |
| DOI: | 10.1111/nep.14306 |
| PMID: | 38626950 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1440-1797 |
|---|---|
| DOI: | 10.1111/nep.14306 |